Ildong Holdings Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 01:56 am EDT
Share
Ildong Holdings Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 7,531.33 million compared to KRW 2,050.18 million a year ago. Net income was KRW 11,699.05 million compared to net loss of KRW 852.74 million a year ago. Basic earnings per share from continuing operations was KRW 1,036 compared to basic loss per share from continuing operations of KRW 76 a year ago. Basic earnings per share was KRW 1,036 compared to basic loss per share of KRW 76 a year ago.
For the six months, sales was KRW 10,519.71 million compared to KRW 4,078.24 million a year ago. Net loss was KRW 43,061 million compared to KRW 14,297.96 million a year ago. Basic loss per share from continuing operations was KRW 3,813 compared to KRW 1,266 a year ago. Basic loss per share was KRW 3,813 compared to KRW 1,266 a year ago.
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
ILDONG HOLDINGS CO., LTD. 